## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the supplied abstract text
- **Shared manuscript claim summary** The authors report the synthesis of four novel imidazole derivatives (5a-d) via click chemistry, their characterization by mass spectrometry and 1H NMR, and computational evaluation (molecular docking, quantum mechanical calculations, molecular dynamics with DCCM analysis, and MMPBSA free energy calculations) to propose these compounds as inhibitors of the LasR transcriptional activator in Pseudomonas aeruginosa, with compound 5a identified as the most potent candidate.
- **Visible evidence base** Abstract text only; no figures, tables, methods details, or supplementary materials provided
- **Missing materials affecting confidence** Full manuscript, experimental procedures, spectral data, docking poses, MD simulation parameters, convergence criteria, statistical analyses, and any experimental validation of anti-biofilm activity

## Reviewer
- **Overall assessment** The abstract presents a computational and synthetic chemistry study with a stated biological goal of identifying LasR inhibitors with anti-biofilm potential. The synthetic work and computational pipeline are plausible in outline, but the abstract contains several internal inconsistencies, unsupported claims, and a critical mismatch between the title's promise of "anti-biofilm screening" and the absence of any experimental biofilm assay data. The claim of being the "first" to report such inhibitors is not substantiated. The evidence base is too thin to establish the central conclusions.
- **Who would be interested in the results, and why** Researchers in antimicrobial drug discovery, particularly those focused on Pseudomonas aeruginosa virulence regulation and biofilm formation, may find the computational screening approach of interest. Computational chemists working on LasR-ligand interactions and imidazole-based scaffolds could also be interested. However, the lack of experimental validation limits the appeal to a broader microbiological audience.
- **Major strengths** The study addresses a clinically relevant problem, namely biofilm-mediated drug resistance in P. aeruginosa. The use of multiple computational techniques (docking, QM, MD, MMPBSA) to cross-validate binding predictions is methodologically reasonable. The synthesis of novel imidazole derivatives via click chemistry is a concrete experimental contribution.
- **Major Concerns** See detailed items below.
- **Minor Comments** See detailed items below.
- **Technical failings that need to be addressed before the case is established** R1-M1 (title-abstract mismatch), R1-M2 (unsupported "first report" claim), R1-M3 (inconsistent energy units), R1-M4 (unsubstantiated correlation between QM descriptors and binding potency), R1-M5 (lack of experimental validation for anti-biofilm claims)
- **Assessment against Nature-style criteria** Originality: The claim of novelty is unverified and the approach, while combining multiple methods, is not conceptually new. Scientific importance: The problem is important, but the evidence does not yet demonstrate a meaningful advance. Interdisciplinary readership: The work could appeal to both chemists and biologists, but the abstract is too sparse to engage either community effectively. Technical soundness: The computational methods are standard, but the reporting is incomplete and internally inconsistent, preventing assessment of rigor. Readability for nonspecialists: The abstract is poorly structured, with grammatical errors and unclear logical flow, which would hinder comprehension by a broad audience.
- **Recommendation posture** Currently not established from the provided evidence. The abstract does not support the title's claim of anti-biofilm screening, and the computational results are reported with inconsistencies that preclude confidence. A revised manuscript with experimental biofilm data, corrected energy units, and a more cautious framing of novelty would be required for a supportive posture.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Claim-evidence alignment
- **Claim pointer** The title states "anti-biofilm screening" and "anti-biofilm inhibition mechanism," implying experimental biofilm assays were performed.
- **Evidence pointer** Abstract text, title
- **Concern** The abstract describes only synthesis, characterization, and computational studies. No experimental biofilm inhibition assay, minimum inhibitory concentration data, or any biological testing is mentioned. The title's promise of "anti-biofilm screening" is therefore not fulfilled by the reported evidence.
- **Why it matters** The title and abstract create an expectation of experimental validation that is not met. This misrepresentation could mislead readers about the study's scope and the strength of the conclusions regarding anti-biofilm activity.
- **Resolution test** Provide experimental biofilm inhibition data (e.g., crystal violet assay, confocal microscopy) or revise the title and abstract to accurately reflect the computational nature of the study.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Novelty claim
- **Claim pointer** "As best of our knowledge, current study first time reports the most potent inhibitors of LasR... utilizing newly functionalized imidazoles (5a-d)"
- **Evidence pointer** Abstract text, location not provided
- **Concern** The claim of being the first to report potent LasR inhibitors using imidazoles is made without any literature comparison or citation. The phrase "most potent" is also unsupported, as no comparative potency data against known inhibitors are provided.
- **Why it matters** Novelty is a central claim in any study. Without a systematic literature review or comparative analysis, this assertion cannot be evaluated and may be inaccurate, which would undermine the study's contribution.
- **Resolution test** Include a literature search summary and comparative potency data against established LasR inhibitors, or temper the novelty claim to be specific and verifiable.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Data consistency
- **Claim pointer** Docking binding energies are reported as "5a - 10.33, 5b -10.09, 5c - 10.11, and 5d -8.33 KJ/mol" and MMPBSA free energy for 5a as "-65.22kj/mol"
- **Evidence pointer** Abstract text, location not provided
- **Concern** Docking scores are typically reported in kcal/mol, not kJ/mol. A value of -10.33 kJ/mol would be approximately -2.47 kcal/mol, which is unusually weak for a specific inhibitor. The MMPBSA value of -65.22 kJ/mol (approximately -15.6 kcal/mol) is more plausible. The inconsistency in units across the two methods is confusing and may indicate an error in reporting.
- **Why it matters** Incorrect or inconsistent energy units undermine the quantitative claims and prevent meaningful comparison with other studies. This is a fundamental technical error that affects the interpretation of all binding affinity results.
- **Resolution test** Clarify the units used for each calculation and ensure consistency. If docking scores are in kcal/mol, correct the values accordingly. Provide a table with all energies in standardized units.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Correlation claim
- **Claim pointer** "HOMO/LUMO and potential energy surface map estimation showed the ligands(5a) with lower energy gaps and larger dipole moments had relatively larger binding potency"
- **Evidence pointer** Abstract text, location not provided
- **Concern** The abstract states that lower HOMO-LUMO gaps and larger dipole moments correlate with higher binding potency, but only compound 5a is mentioned as an example. No data for compounds 5b-d are provided to support a general correlation. The relationship between QM descriptors and docking scores is asserted without statistical analysis.
- **Why it matters** A claimed correlation across four compounds requires data for all compounds and some measure of statistical significance. Without this, the statement is anecdotal and cannot be used to support the mechanistic interpretation.
- **Resolution test** Provide a table or figure showing HOMO-LUMO gaps, dipole moments, and binding energies for all four compounds, with a correlation analysis (e.g., R-squared value).

- **Concern ID** R1-M5
- **Severity** Major
- **Blocking** Yes
- **Axis** Biological validation
- **Claim pointer** The study aims to "explore their anti-biofilm inhibition mechanism against Pseudomonas Aeruginosa"
- **Evidence pointer** Abstract text, location not provided
- **Concern** The abstract reports only computational predictions of LasR binding. No experimental validation of LasR inhibition, biofilm reduction, or any phenotypic effect on P. aeruginosa is presented. The mechanism of anti-biofilm action is therefore entirely speculative.
- **Why it matters** Computational predictions alone cannot establish a biological mechanism. Without experimental confirmation, the clinical or translational relevance of these compounds remains unproven, and the study's central claim is not supported.
- **Resolution test** Include experimental data such as LasR reporter assays, biofilm inhibition assays, or gene expression analysis in P. aeruginosa treated with the compounds.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract structure
- **Evidence pointer** Abstract text
- **Issue** The abstract contains incomplete sentences and grammatical errors, such as "The binding potency and mode of biding of ligands." and "The significant change in the structural dynamics of LasR protein due to complex formation with newlyfunctionalized imidazoles ligands."
- **Required correction** Revise the abstract for grammatical correctness and clarity. Complete the incomplete sentence and ensure all statements are grammatically sound.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Methodological detail
- **Affected element** MD simulation description
- **Evidence pointer** Abstract text
- **Issue** The abstract mentions "Dynamics cross correlation matrix (DCCMs) and protein surface analysis" but provides no details on simulation length, force field, or system setup. This is insufficient for reproducibility.
- **Required correction** Add brief methodological details in the abstract or refer to a methods section where these parameters are specified.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Terminology
- **Affected element** "click approach"
- **Evidence pointer** Abstract text
- **Issue** The term "click approach" is used without specifying the type of click reaction (e.g., copper-catalyzed azide-alkyne cycloaddition). This is imprecise.
- **Required correction** Specify the exact click chemistry method used for synthesis.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Data presentation
- **Affected element** Characterization data
- **Evidence pointer** Abstract text
- **Issue** The abstract states compounds were characterized by "Mass Spectrometry and 1H NMR" but provides no spectral data or purity information.
- **Required correction** Include key spectral data (e.g., HRMS values, characteristic NMR shifts) or refer to supplementary material where full data are available.

## Risk / unsupported claims
- The claim of being the "first" to report potent LasR inhibitors with imidazole derivatives is unsupported by any literature comparison.
- The assertion that lower HOMO-LUMO gaps and larger dipole moments correlate with higher binding potency is unsupported, as data for all compounds are not provided.
- The title's implication of anti-biofilm screening is unsupported, as no experimental biofilm data are presented.
- The binding energy values in kJ/mol for docking are likely erroneous and cannot be evaluated without clarification.
- The mechanistic interpretation of anti-biofilm inhibition is entirely speculative, as no biological experiments are described.